<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02638974</url>
  </required_header>
  <id_info>
    <org_study_id>15438</org_study_id>
    <nct_id>NCT02638974</nct_id>
  </id_info>
  <brief_title>Skin Camouflage for Women Prisoners With Self-Harm Scarring</brief_title>
  <acronym>COVER</acronym>
  <official_title>Feasibility and Acceptability of Medical Skin Camouflage for Recovery of Women With Self-Harm Scarring in Prison</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manchester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women prisoners are more likely to commit suicide or self-harm than women in the community or&#xD;
      male prisoners.&#xD;
&#xD;
      Healthcare services have improved how they manage self-harm in the community and prisons.&#xD;
      However, there has been little focus on the recovery of people with self-harm scars. Medical&#xD;
      skin camouflage (MSC) is a British National Formulary-listed topical cream designed to cover&#xD;
      skin conditions. Research on MSC has focused on its use with non-self-harm marks e.g. burns.&#xD;
      The evidence from this research suggests that the cream helps women feel better and do more&#xD;
      activities. There is little/no evidence about the effects of the preparation for women who&#xD;
      self-harm and for prisoners.&#xD;
&#xD;
      This research was funded by the National Institute for Health Research Research for Patient&#xD;
      Benefit Programme. In the research the investigators will examine whether it is possible and&#xD;
      practical to use MSC in prison. The investigators will ask women prisoners and staff what&#xD;
      they think about the cream. The research has four parts. In the first part the investigators&#xD;
      will run focus groups with women prisoners and prison staff to find out the best way to&#xD;
      deliver the MSC intervention and how to measure its effects. In the second part the&#xD;
      investigators will design a programme for delivering the MSC. The investigators will then&#xD;
      train 6-10 long-term prisoners to become skin camouflage practitioners. The final part will&#xD;
      involve a small randomised controlled trial with 40 women prisoners; 20 will be allocated to&#xD;
      the intervention group and will use the MSC for 6 weeks. The investigators will measure their&#xD;
      mood, thoughts of self-harm and wellbeing before and after they use MSC. The investigators&#xD;
      will compare these results with 20 women who have not used MSC (waitlist control group). All&#xD;
      women taking part will be placed at random into the control or the treatment group. The&#xD;
      control group will receive the MSC after the research has ended.&#xD;
&#xD;
      Potential benefits of this study may be an increase in self-esteem and quality of life for&#xD;
      the women prisoners. As women recover they may be less likely to self-harm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to establish the feasibility and acceptability of the use of medical skin&#xD;
      camouflage for self-harm scarring in a women's prison. The investigators are interested in&#xD;
      the use of medical skin camouflage by women who are recovering from self-harm. The research&#xD;
      location is a Closed Category prison for female adults and young offenders in England. The&#xD;
      study will involve adult women prisoners (over 18) and staff at the prison.&#xD;
&#xD;
      Medical Skin Camouflage uses specialised creams/powders to disguise skin conditions or&#xD;
      scarring with the intention of normalising the appearance of the skin. Studies which have&#xD;
      examined the use of medical skin camouflage for dermatological diseases or burns have&#xD;
      reported significant psychological benefits and social benefits. Preliminary findings from&#xD;
      co-applicant Dr Sandeep Ranote's work, with young people who self-harm in the community,&#xD;
      indicate that the use of medical skin camouflage can lead to increased well-being, confidence&#xD;
      and ability to partake in social activities. Currently there is no evidence on the use of MSC&#xD;
      for self-harm scarring in prisons.&#xD;
&#xD;
      The research design is intended to provide information necessary to decide whether it is&#xD;
      feasible and acceptable to conduct a full scale randomised controlled trial of MSC in a&#xD;
      women's prison. The four phases of the research are as follows:&#xD;
&#xD;
      Phase 1: Focus groups in prison. Interested prisoners and staff will be provided with an&#xD;
      information sheet about phase 1 of the project and will have up to 48 hours to decide whether&#xD;
      they want to take part in this phase of the research. After consent the investigators will&#xD;
      conduct 2 focus groups with women prisoners (including current self-harmers) and prison staff&#xD;
      (6-10 in each group; 12-20 in total). The focus groups are designed to achieve two aims: to&#xD;
      ensure that appropriate outcome measures are used in the phase four pilot trial; and to&#xD;
      explore any barriers to the delivery of medical skin camouflage in a prison environment. The&#xD;
      focus groups will last 60-90 minutes.&#xD;
&#xD;
      In the groups the investigators shall explore the following:&#xD;
&#xD;
        1. Any potential problems with the introduction of MSC.&#xD;
&#xD;
        2. How training long-term prisoners as camouflage practitioners will be undertaken (see&#xD;
           phase 3).&#xD;
&#xD;
        3. With women prisoners: the investigators will discuss how scarring affects mood,&#xD;
           self-esteem, self-confidence, resilience, and how others perceive them. These questions&#xD;
           will be designed to assess how best to collate information about how scarring affects&#xD;
           prisoner's lives and their mental health informing which outcomes should be measured in&#xD;
           phase 4. Part of this consultation will involve asking them to help us adapt standard&#xD;
           measures of wellbeing (such as WEMWES) so they are appropriate for a prison environment.&#xD;
&#xD;
        4. The investigators will also discuss the use of Assessment, Care in Custody and Teamwork&#xD;
           data (ACCT) and Inpatient Mental Health Records during the pilot trial. Prisoners who&#xD;
           are at risk of self-harm are assessed by the prison Safer Custody team who follow the&#xD;
           ACCT procedures which include recording incidents of self-harm.&#xD;
&#xD;
      The focus groups will be recorded, transcribed and checked for accuracy. The data will be&#xD;
      analysed by members of the research team. To mitigate against possible researcher bias, an&#xD;
      independent experienced researcher will review the findings.&#xD;
&#xD;
      During phase 1 members of the research team will also be trained to become medical skin&#xD;
      camouflage practitioners. This training will be delivered by Changing Faces, a third-sector&#xD;
      organisation. Training is accredited by the Royal College of Nursing (2012). This training&#xD;
      will be done in preparation for phase 3.&#xD;
&#xD;
      Phase 2: Guidance protocol&#xD;
&#xD;
      Using the findings from phase 1, the investigators will refine the study processes and&#xD;
      procedures ready for the next two phases. This will involve:&#xD;
&#xD;
        1. The production of a guidance protocol for the use of medical skin camouflage in prisons.&#xD;
           The protocol will focus on practical aspects of where, when and how treatment is&#xD;
           delivered, who applies it; how it is applied; how it is prescribed, and storage of&#xD;
           prescribed products.&#xD;
&#xD;
        2. Finalising how the training of lifers will be delivered and supported (in preparation&#xD;
           for phase 3). This includes adapting the Changing Faces training manual so it is&#xD;
           suitable for use with women prisoners.&#xD;
&#xD;
        3. Finalising the eligibility criteria for phase 4, e.g. how assessment will be made of&#xD;
           self-harm scar wounds and how women will be referred to the trial.&#xD;
&#xD;
        4. Finalising the outcome measures to be used in phase 4.&#xD;
&#xD;
        5. If necessary, refining our standard operating procedures for monitoring and managing any&#xD;
           incidents of self-harm during the intervention.&#xD;
&#xD;
      Phase 3: Training lifers This phase of the research involves the training of long-term&#xD;
      prisons (lifers) to deliver the medical skin camouflage intervention to the women prisoners&#xD;
      in phase 4. By training lifers to deliver the intervention the investigators will ensure that&#xD;
      women prisoners are integral to the delivery of camouflage to other women offenders. Not only&#xD;
      does this genuinely include stakeholders in research, but it also builds sustainable capacity&#xD;
      within the prison and is likely to increase self-efficacy/self-worth of those women.&#xD;
&#xD;
      In phase 3 the MSC trained research team members will implement a rolling programme of&#xD;
      training and support for 6 or more long-term women prisoners so they are able to deliver the&#xD;
      MSC intervention. During this phase and in phase 4, the research team will provide regular&#xD;
      mentoring and advice on practical aspects of the product use. The women lifers will receive&#xD;
      ongoing supportive liaison throughout the project from members of the research team.. The&#xD;
      project manager will liaise with the prison lifers to ensure fidelity to the guidance&#xD;
      protocol.&#xD;
&#xD;
      Phase 4 Phase 4 is a small scale randomised wait list control pilot. A sample of 40 women&#xD;
      prisoners with self-harm scarring at the prison will be recruited; 20 participants will be&#xD;
      randomised to receive the 6 week camouflage intervention; 20 participants will become&#xD;
      wait-list controls and receive the intervention after completion of the 6-week trial. The&#xD;
      trial participants will be remand and sentenced women prisoners screened for date of release,&#xD;
      with at least 6 weeks left on their sentence and self-harm scarring, with closed wounds (to&#xD;
      allow the MSC to be applied).&#xD;
&#xD;
      Eligible female prisoners will be identified by the prison, for example using information&#xD;
      known by the Safer Custody team. Once identified the research team will provide the potential&#xD;
      participants with an information sheet. Following earlier research in prisons, the&#xD;
      investigators envisage that potential participants will be allocated a research number&#xD;
      assuring anonymity from the research team. This process will allow the researchers to send&#xD;
      out participant information sheets to relevant potential participants and allow participants&#xD;
      to make an informed decision about participation prior to identifying themselves to&#xD;
      researchers. Potential participants will be given 24-48 hours to decide whether they want to&#xD;
      consent to involvement. The Clinical Research Network will assist the research assistant with&#xD;
      the recruitment to the pilot trial.&#xD;
&#xD;
      A member of the research team will interview all the women at the start of the trial&#xD;
      collecting information on the following:&#xD;
&#xD;
        1. Basic demographics (Bespoke Personal History Questionnaire)&#xD;
&#xD;
        2. History of self-harm (Deliberate Self-harm Inventory)&#xD;
&#xD;
        3. Mood (Beck Depression Inventory II, Beck Scale for Suicidal Ideation, Beck Hopelessness&#xD;
           Scale)&#xD;
&#xD;
        4. Psychosocial well-being (Warwick Edinburgh Mental Wellbeing Scale) and self-esteem&#xD;
           (Rosenberg Self-esteem Scale)&#xD;
&#xD;
        5. Health-related quality of life (SF-12 and EQ5D) and quality of life related to scarring&#xD;
           (Prison-adapted Dermatology Quality of Life Index)&#xD;
&#xD;
        6. Zanarini Rating Scale for Borderline Personality Disorder With women's permission the&#xD;
           research team will record key clinical characteristics from CNomis, SystemOne (the&#xD;
           prison electronic medical records) and from ACCT documentation.&#xD;
&#xD;
      The MSC treatment will be provided for 6 weeks. The trained long-term prisoners will run&#xD;
      regular 1 hour appointments for women in the intervention group. During this appointment, the&#xD;
      participant will receive information about the specially formulated MSC creams. The lifers&#xD;
      will take them through the skin tone colour-matching process and will try small amounts of&#xD;
      cream until they find a match. After this, they will apply the cream to a larger area and use&#xD;
      special powders to set the cream and make sure it is waterproof. Throughout the appointment,&#xD;
      an explanation of what they are doing will be given to participants and the participant will&#xD;
      then be able to try applying the camouflage creams themselves. When they are happy with how&#xD;
      it looks, the practitioner will complete a prescription form that will be processed by a&#xD;
      nurse prescriber. The prescription will provide them with one cream and one powder which we&#xD;
      anticipate will last for 3-6 months. During the intervention the research team will record&#xD;
      data on new self-harm incidents and related life-events (using ACCT data and Inpatient mental&#xD;
      health records). All participants will also be asked to complete a weekly diary to record&#xD;
      their self-harm experiences (thoughts and acts) during the trial.&#xD;
&#xD;
      At the end of the 6 weeks the research team will meet with participants to collect post&#xD;
      intervention data. Initial post-intervention testing is at 6 weeks as the average sentence&#xD;
      length for women in the prison. Six weeks post-intervention the investigators will repeat&#xD;
      baseline measures apart from the demographic questionnaire. A final follow-up will be piloted&#xD;
      at 3-months post-baseline. Recruitment, participation, retention and causes of drop-out will&#xD;
      also be collected.&#xD;
&#xD;
      Post-intervention the investigators will conduct qualitative interviews with the following&#xD;
      groups:&#xD;
&#xD;
        1. All women who received the intervention will be invited to participate in an interview&#xD;
           to explore their experience of the intervention and its acceptability. The investigators&#xD;
           will explore the participants views on treatment accessibility and potential impact on&#xD;
           how women feel about their scarring, mood, self-esteem and self-confidence.&#xD;
&#xD;
        2. All women in the waitlist control group will be invited to participate in an interview&#xD;
           to explore their experiences of being randomised to the control group and participating&#xD;
           in the research.&#xD;
&#xD;
        3. 6-10 prison health and other staff who have direct contact with the participants will&#xD;
           take part in a focus group. This will explore their views in relation to the treatments'&#xD;
           acceptability and perceived effects on participants' well-being, quality of life and&#xD;
           everyday functioning.&#xD;
&#xD;
        4. Interviews will be conducted with the lifers who delivered the intervention exploring&#xD;
           how acceptable the training was, how MSC was used with the participants, feedback on the&#xD;
           mentoring and support and any benefits or difficulties working with participants.&#xD;
&#xD;
      During the course of the research the investigators will also be exploring the best way to&#xD;
      calculate the resource use associated with providing MSC in prisons. The investigators shall&#xD;
      develop a bespoke resource use questionnaire to pilot the collection of resource use data&#xD;
      concerning the delivery of the intervention, including time spent by Changing Faces training&#xD;
      the research team, time spent by trained prisoners delivering the intervention, and&#xD;
      quantities of MSC products used and prescribed. Descriptive analysis of this data will inform&#xD;
      future trial design.&#xD;
&#xD;
      The Secure Facilities Service Use Schedule (SF-SUS) will be used to collect other relevant&#xD;
      resource-use at 3month follow-up: contact with personal, Safer custody and general prison&#xD;
      officers, and staff from mental health team; time on one-to-one observation, specialist&#xD;
      mental health units; recording observations and care plans. SF-SUS records individual-level&#xD;
      data on service use within secure facilities and external services for economic evaluation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 29, 2016</start_date>
  <completion_date type="Actual">June 1, 2018</completion_date>
  <primary_completion_date type="Actual">June 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Warwick-Edinburgh Mental Well-being Scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>WEMWBS, Minimum: 14 Maximum: 70. Higher scores represent higher mental wellbeing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Becks Scale for Suicidal Ideation</measure>
    <time_frame>6 weeks</time_frame>
    <description>BSS MInimum: 0 Maximum: 28. The higher the score the greater the suicidal ideation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Becks Depression Inventory</measure>
    <time_frame>6 weeks</time_frame>
    <description>BDI-II Minimum: 0 Maximum: 63. 0-13 indicates minimal depression; 14-19 mild depression; 20-28 moderate depression and 29-63 severe depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Becks Hopelessness Scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>BHS, Minimum: 0 Maximum: 20. 0-3 indicates No or minimal hopelessness; 4-8 is mild; 9-14 is moderate and 15+ is severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rosenberg Self-Esteem Scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>RSE Minimum: 0 Maximum: 30 Higher scores represent higher self-esteem</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adapted-DQLI</measure>
    <time_frame>6 weeks</time_frame>
    <description>Adapted-DQLI Minimum: 0 Maximum: 24 The higher the score on the Dermatology Quality of Life Index the more impaired the quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Self Injurious Behaviour</condition>
  <arm_group>
    <arm_group_label>Medical Skin Camouflage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will use medical skin camouflage for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wait List Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm will receive medical skin camouflage at the end of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical Skin Camouflage</intervention_name>
    <description>Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions</description>
    <arm_group_label>Medical Skin Camouflage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Remand and sentenced women prisoners screened for date of release with at least 6&#xD;
             weeks left on their sentence&#xD;
&#xD;
          -  Self-harm scarring, with closed wounds (to allow the MSC to be applied).&#xD;
&#xD;
          -  Able to give written, informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women prisoners with open wounds&#xD;
&#xD;
          -  Less than 6 weeks on anticipated release date&#xD;
&#xD;
          -  Women with skin conditions and allergies&#xD;
&#xD;
          -  Women prisoners who lack the capacity to consent to the research.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn Abel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manchester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Styal Prison</name>
      <address>
        <city>Wilmslow</city>
        <state>Cheshire</state>
        <zip>SK9 4HR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 18, 2015</study_first_submitted>
  <study_first_submitted_qc>December 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2015</study_first_posted>
  <results_first_submitted>May 30, 2019</results_first_submitted>
  <results_first_submitted_qc>September 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 18, 2019</results_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Manchester</investigator_affiliation>
    <investigator_full_name>Kerry Gutridge</investigator_full_name>
    <investigator_title>Project Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Self-Injurious Behavior</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02638974/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Medical Skin Camouflage</title>
          <description>This arm will use medical skin camouflage for 6 weeks&#xD;
Medical Skin Camouflage: Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions</description>
        </group>
        <group group_id="P2">
          <title>Wait List Control</title>
          <description>This arm will receive medical skin camouflage at the end of the study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Medical Skin Camouflage</title>
          <description>This arm will use medical skin camouflage for 6 weeks&#xD;
Medical Skin Camouflage: Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions</description>
        </group>
        <group group_id="B2">
          <title>Wait List Control</title>
          <description>This arm will receive medical skin camouflage at the end of the study</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Participants withdrew from the research</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" lower_limit="21" upper_limit="47"/>
                    <measurement group_id="B2" value="29" lower_limit="19" upper_limit="51"/>
                    <measurement group_id="B3" value="30" lower_limit="19" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Participants withdrew from the research</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Participants withdrew from the research</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-white</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Adapted-Dermatology Quality of Life Index</title>
          <description>Adapted DQLI Minimum 0, Maxium 24. The higher the score ont he DQLI, the more impaired the quality of life.</description>
          <population>Participants withdrew from the study so their data was not analysed</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.6957" spread="3.95928"/>
                    <measurement group_id="B2" value="12.2609" spread="6.51723"/>
                    <measurement group_id="B3" value="12.4783" spread="5.33641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beck's Depression Inventory</title>
          <description>BDI-II Minimum 0 Maximum 63. 0-13 indicates minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression</description>
          <population>Participants withdrew from the research</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.6957" spread="11.39950"/>
                    <measurement group_id="B2" value="38.9565" spread="6.99011"/>
                    <measurement group_id="B3" value="36.3261" spread="9.72066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beck's Hopelessness Scale</title>
          <description>BHS Minimum 0 Maximum 20. 0-3 indicates no or minimal hopelessness, 4-8 is mild, 9-14 is moderate and 15+ is severe</description>
          <population>Participants withdrew from the research.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.0000" spread="5.86980"/>
                    <measurement group_id="B2" value="14.6957" spread="4.43575"/>
                    <measurement group_id="B3" value="12.3478" spread="5.66556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beck's Scale for Suicide Ideation</title>
          <description>BSS Minimum 0 Maximum 28. The higher the score the greater the suicidal ideation.</description>
          <population>Participants withdrew from the research or decline to answer this scale</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.2273" spread="7.75783"/>
                    <measurement group_id="B2" value="8.8636" spread="8.66463"/>
                    <measurement group_id="B3" value="7.5455" spread="8.23621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Warwick-Edinburgh Mental Wellbeing Scale</title>
          <description>WEMWBS Minimum 14 Maximum 70. Higher scores represent higher wellbeing</description>
          <population>Participants withdrew from the research.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.0435" spread="11.17008"/>
                    <measurement group_id="B2" value="30.2609" spread="9.12647"/>
                    <measurement group_id="B3" value="33.1522" spread="10.50072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rosenberg Self Esteem Scale</title>
          <description>RSE Minimum 0 Maximum 30. Higher scores represent higher self esteem.</description>
          <population>Participants withdrew from the research</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.6522" spread="4.68662"/>
                    <measurement group_id="B2" value="9.6087" spread="3.38095"/>
                    <measurement group_id="B3" value="10.6304" spread="4.17058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Warwick-Edinburgh Mental Well-being Scale</title>
        <description>WEMWBS, Minimum: 14 Maximum: 70. Higher scores represent higher mental wellbeing</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Medical Skin Camouflage</title>
            <description>This arm will use medical skin camouflage for 6 weeks&#xD;
Medical Skin Camouflage: Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions</description>
          </group>
          <group group_id="O2">
            <title>Wait List Control</title>
            <description>This arm will receive medical skin camouflage at the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Warwick-Edinburgh Mental Well-being Scale</title>
          <description>WEMWBS, Minimum: 14 Maximum: 70. Higher scores represent higher mental wellbeing</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1739" spread="8.97295"/>
                    <measurement group_id="O2" value="30.8182" spread="8.46076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Becks Scale for Suicidal Ideation</title>
        <description>BSS MInimum: 0 Maximum: 28. The higher the score the greater the suicidal ideation.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Medical Skin Camouflage</title>
            <description>This arm will use medical skin camouflage for 6 weeks&#xD;
Medical Skin Camouflage: Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions</description>
          </group>
          <group group_id="O2">
            <title>Wait List Control</title>
            <description>This arm will receive medical skin camouflage at the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Becks Scale for Suicidal Ideation</title>
          <description>BSS MInimum: 0 Maximum: 28. The higher the score the greater the suicidal ideation.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0435" spread="10.20463"/>
                    <measurement group_id="O2" value="4.9412" spread="6.76822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Becks Depression Inventory</title>
        <description>BDI-II Minimum: 0 Maximum: 63. 0-13 indicates minimal depression; 14-19 mild depression; 20-28 moderate depression and 29-63 severe depression</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Medical Skin Camouflage</title>
            <description>This arm will use medical skin camouflage for 6 weeks&#xD;
Medical Skin Camouflage: Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions</description>
          </group>
          <group group_id="O2">
            <title>Wait List Control</title>
            <description>This arm will receive medical skin camouflage at the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Becks Depression Inventory</title>
          <description>BDI-II Minimum: 0 Maximum: 63. 0-13 indicates minimal depression; 14-19 mild depression; 20-28 moderate depression and 29-63 severe depression</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6957" spread="16.93687"/>
                    <measurement group_id="O2" value="35.1364" spread="8.45884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Becks Hopelessness Scale</title>
        <description>BHS, Minimum: 0 Maximum: 20. 0-3 indicates No or minimal hopelessness; 4-8 is mild; 9-14 is moderate and 15+ is severe</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Medical Skin Camouflage</title>
            <description>This arm will use medical skin camouflage for 6 weeks&#xD;
Medical Skin Camouflage: Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions</description>
          </group>
          <group group_id="O2">
            <title>Wait List Control</title>
            <description>This arm will receive medical skin camouflage at the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Becks Hopelessness Scale</title>
          <description>BHS, Minimum: 0 Maximum: 20. 0-3 indicates No or minimal hopelessness; 4-8 is mild; 9-14 is moderate and 15+ is severe</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3636" spread="5.57670"/>
                    <measurement group_id="O2" value="12.0000" spread="6.11010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rosenberg Self-Esteem Scale</title>
        <description>RSE Minimum: 0 Maximum: 30 Higher scores represent higher self-esteem</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Medical Skin Camouflage</title>
            <description>This arm will use medical skin camouflage for 6 weeks&#xD;
Medical Skin Camouflage: Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions</description>
          </group>
          <group group_id="O2">
            <title>Wait List Control</title>
            <description>This arm will receive medical skin camouflage at the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Rosenberg Self-Esteem Scale</title>
          <description>RSE Minimum: 0 Maximum: 30 Higher scores represent higher self-esteem</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8696" spread="4.21366"/>
                    <measurement group_id="O2" value="12.1818" spread="4.39303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adapted-DQLI</title>
        <description>Adapted-DQLI Minimum: 0 Maximum: 24 The higher the score on the Dermatology Quality of Life Index the more impaired the quality of life</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Medical Skin Camouflage</title>
            <description>This arm will use medical skin camouflage for 6 weeks&#xD;
Medical Skin Camouflage: Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions</description>
          </group>
          <group group_id="O2">
            <title>Wait List Control</title>
            <description>This arm will receive medical skin camouflage at the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Adapted-DQLI</title>
          <description>Adapted-DQLI Minimum: 0 Maximum: 24 The higher the score on the Dermatology Quality of Life Index the more impaired the quality of life</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7391" spread="5.42902"/>
                    <measurement group_id="O2" value="11.9091" spread="6.11718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Medical Skin Camouflage</title>
          <description>This arm will use medical skin camouflage for 6 weeks&#xD;
Medical Skin Camouflage: Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions</description>
        </group>
        <group group_id="E2">
          <title>Wait List Control</title>
          <description>This arm will receive medical skin camouflage at the end of the study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Kerry Gutridge, Trial Manager</name_or_title>
      <organization>University of Manchester</organization>
      <phone>0161-306-7931</phone>
      <email>kerry.gutridge@manchester.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

